BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12098004)

  • 21. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gram-scale synthesis of pinusolide and evaluation of its antileukemic potential.
    Shults EE; Velder J; Schmalz HG; Chernov SV; Rubalova TV; Gatilov YV; Henze G; Tolstikov GA; Prokop A
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4228-32. PubMed ID: 16781150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of glufosfamide in childhood acute leukemia.
    Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
    Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
    Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
    Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
    Mitchell CD; Richards SM; Kinsey SE; Lilleyman J; Vora A; Eden TO;
    Br J Haematol; 2005 Jun; 129(6):734-45. PubMed ID: 15952999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
    Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
    Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study.
    Kaspers GJ; Zwaan CM; Veerman AJ; Rots MG; Pieters R; Bucsky P; Domula M; Göbel U; Graf N; Havers W; Jorch N; Kabisch K; Spaar HJ; Ritter J; Creutzig U
    Klin Padiatr; 1999; 211(4):239-44. PubMed ID: 10472557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
    Klumper E; Pieters R; Kaspers GJ; Huismans DR; Loonen AH; Rottier MM; van Wering ER; van der Does-van den Berg A; Hählen K; Creutzig U
    Leukemia; 1995 Nov; 9(11):1864-9. PubMed ID: 7475276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
    Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
    Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.
    Beesley AH; Weller RE; Senanayake S; Welch M; Kees UR
    Leuk Res; 2009 Feb; 33(2):321-5. PubMed ID: 18789525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
    Janiszewska H; Styczynski J; Kolodziej B; Wysocki M; Haus O
    Ann Hematol; 2009 Dec; 88(12):1193-8. PubMed ID: 19352661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
    Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
    Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
    Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
    Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.
    Ito C; Evans WE; McNinch L; Coustan-Smith E; Mahmoud H; Pui CH; Campana D
    J Clin Oncol; 1996 Aug; 14(8):2370-6. PubMed ID: 8708730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
    Styczynski J; Wysocki M; Dluzniewska A; Juraszewska E; Balwierz W; Czyzewski K; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Stanczak E; Malinowska I; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Kapuscinska L; Szczepanek J; Kolodziej B; Rafinska B; Kubicka M
    Anticancer Res; 2008; 28(3B):1927-31. PubMed ID: 18630483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia.
    Erduran E; Tekelioglu Y; Karakas T; Gedik Y; Mert FM
    Pediatr Hematol Oncol; 2006; 23(7):587-98. PubMed ID: 16928654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.